Drugs that target the endocannabinoid system are of interest as pharmacological options to
combat cancer and to improve the life quality of cancer patients. From this perspective …

Over the past years, several lines of evidence support a therapeutic potential of Cannabis
derivatives and in particular phytocannabinoids. Δ 9-THC and cannabidiol (CBD) are the …

Glioblastoma multiforme (GBM), a grade IV astrocytoma, is the most common and deadly
type of primary malignant brain tumor, with a patient's median survival rate ranging from 15 …

In addition to the well-known palliative effects of cannabinoids on some cancer-associated
symptoms, a large body of evidence shows that these molecules can decrease tumour …

In recent years, the endocannabinoid system has received great interest as a potential
therapeutic target in numerous pathological conditions. Cannabinoids have shown an …

Inhibitor of DNA binding (ID) proteins are transcriptional regulators that control the timing of
cell fate determination and differentiation in stem and progenitor cells during normal …

Glioblastoma (GBM) resistance to therapy is the most common cause of tumor recurrence,
which is ultimately fatal in 90% of the patients 5 years after initial diagnosis. A sub …

The pharmacological importance of cannabinoids has been in study for several years.
Cannabinoids comprise of (a) the active compounds of the Cannabis sativa plant,(b) …

The endocannabinoid system has emerged as an important target for the treatment of many
diverse diseases. In addition to the well‐established palliative effects of cannabinoids in …

Glioblastoma is the most common and most aggressive primary brain malignancy. The
current initial standard of care consists of maximal safe surgical resection followed by radical …